<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>KEYTRUDA® Approval on FinanClub</title>
    <link>https://finan.club/tags/keytruda-approval/</link>
    <description>Recent content in KEYTRUDA® Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 11 Sep 2023 05:47:14 +0000</lastBuildDate><atom:link href="https://finan.club/tags/keytruda-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Mon, 11 Sep 2023 05:47:14 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:107
Chances: Merck &amp;amp; Co., Inc. (MRK) is a favorite among institutional investors, with 78% institutional ownership, indicating institutional confidence. Merck received approval to expand the indication of its ERVEBO® Ebola Zaire Vaccine to include children aged 1 year and older, potentially expanding its market.</description>
    </item>
    
  </channel>
</rss>
